Novo Nordisk today announced the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for oral semaglutide,
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are especially pronounced in those with
Two drugs commonly prescribed to treat type 2 diabetes carry a high risk of cardiovascular events such as heart attack, stroke, heart failure or
In the largest trial of its kind to determine the cardiovascular outcomes for a new class of diabetes medications, Astra Zeneca’s Farxiga was
Eli Lilly and Company reported that it’s drug, Trulicity® significantly reduced major adverse cardiovascular events, a composite endpoint of
Metformin, a commonly prescribed drug for type 2 diabetes could prevent heart disease in patients with type 1 diabetes -and could lead to the
Eli Lilly and Company’s investigational two-in-one diabetes drug showed both meaningful blood sugar reduction and significant weight loss in
A weight loss drug, lorcaserin, was found to reduce the risk of diabetes by 19 percent in patients with prediabetes in a recent study. The drug is
Tresiba®, an insulin degludec injection, has received an expanded approval for the treatment of Type 1 diabetes in pediatric patients in Canada.
Should metformin remain first-line therapy for type 2 diabetes? It was one of the more light-hearted but hotly-debated presentations at this
Get a little dLife delivered to your inbox every week.
Leave this field empty if you’re human: